

New Isocyanate Antigens for Diagnostic Assays

A.V. Wisniewski¹, Q. Liu¹, A. Cartier², C.T. Holm¹, C.A. Redlich¹. ¹Yale School of Medicine, New Haven, CT; ²Hôpital du Sacré Coeur de Montreal, Montreal, Canada. Email: adam.wisniewski@yale.edu

Hexamethylene diisocyanate (HDI) and other isocyanates are widely used chemicals and a common cause of occupational asthma. Unfortunately, reliable diagnostic tests for isocyanate sensitivity are lacking, and unlike common atopic asthma, RAST/skin prick tests based on specific antigens are frequently negative in isocyanate asthmatics. The apparent lack of isocyanate-specific antibody in sensitized patients may be partly due to the use in diagnostic assays of isocyanate antigens that do not accurately mimic those which occur naturally *in vivo*. We have developed a novel system for generating isocyanate antigens under physiologic conditions, whereby albumin in liquid solution is exposed to vapors of HDI, resulting in HDI-albumin conjugates. These novel vapor/liquid HDI-albumin conjugates perform better in antibody binding assays than those prepared by traditional liquid/liquid phase exposure. Using the vapor/liquid conjugates as antigens: 1) HDI-specific IgE was detected in 6/10 HDI asthmatics tested, compared with 2/10 using liquid/liquid phase exposed antigens, 2) HDI-specific IgG titers were significantly ($p < .001$) associated with exposure in 203 subjects, with fewer false positives than assays performed with liquid/liquid phase exposed antigens. The novel HDI-albumin conjugates are very lightly substituted with HDI (~2-3 mol HDI/albumin) compared with those prepared by liquid/liquid phase exposure. In contrast to liquid/liquid phase exposure, HDI-albumin conjugates are available in multiple sites for HDI conjugation. In contrast to liquid/liquid phase exposure, HDI-albumin conjugates improve immunologic assays for sensitization or disease.

Exhaled Nitric Oxide Measurement in Microwave Popcorn Production Plant Workers

M. Akpınar-Elci¹, K.J. Stemple¹, O.C. Elci¹, R.D. Dweik², K. Kreiss¹, P.L. Enright¹. ¹CDC/ National Institute for Occupational Safety and Health, DRDS, Morgantown, WV; ²Department of Pulmonary and Critical Care Medicine, The Cleveland Clinic Foundation, Cleveland, OH. Email: mra8@cdc.gov

RATIONALE: Two former microwave popcorn production plant workers had pathology consistent with bronchiolitis obliterans. The prevalence of respiratory problems and airways obstruction among current workers were higher than expected. Exhaled nitric oxide (ENO) was measured in workers at risk for developing lung disease. **METHODS:** One hundred thirty five workers completed a questionnaire, spirometry and ENO measurement. Workers with relatively high exposures ($n=107$, mixing, microwave packaging, maintenance, and quality control) were compared to workers with low exposure from other areas of the plant ($n=28$). **RESULTS:** ENO was lower in the 135 current workers (median 5.9 ppb) when compared to an external control group of 31 healthy never smokers (median 7.6 ppb) ($p=0.001$). ENO was lower in the high-risk group of workers (median 5.5 ppb) when compared to the low risk group (median 6.6 ppb) ($p=0.03$). There were no significant associations between ENO and current respiratory symptoms or lung function. However, after adjusting for smoking status, workers with current systemic symptoms were more likely than other workers to have a high ENO [chills OR: 7.8 (95% CI: 1.1-58.3); night sweats OR: 8.3 (95% CI: 1.1-64.6); fever OR: 4.0 (95% CI: 0.9-18.3)]. **CONCLUSION:** In this study of microwave popcorn workers, ENO was not useful for distinguishing between groups of workers with and without respiratory symptoms or lung function abnormalities. However, the association of ENO with systemic symptoms suggests that ENO might be useful in the study of inhalation fever or other inhalation syndromes.

This Abstract is Funded by: None

Hot Tub Associated Granulomatous Lung Disease from Mycobacterial Bioaerosols

C.S. Glazer¹, J.W. Martyny², B. Lee², C.S. Rose². ¹University of Texas Southwestern Medical Center, Dallas, TX; ²National Jewish Medical and Research Center, Denver, CO. Email: craig.glazer@utsouthwestern.edu

Rationale: The spectrum of diseases from nontuberculous mycobacteria (NTM) is expanding, and the incidence of NTM pulmonary disease in immunocompetent hosts is increasing. We describe the clinical, functional, and radiologic features of a series of 27 patients with granulomatous pneumonitis from exposure to hot tub and therapy pool bioaerosols. **Methods:** We reviewed charts of all patients seen in our clinic from 1994-2002 for hypersensitivity pneumonitis (HP, ICD9 code 495.1-495.9). We included all patients whose HP was attributed to a hot tub or therapy pool. **Results:** Median latency between exposure to symptom onset was 10 months (range 2 months to 11 years). Cases reported symptoms of dyspnea (100%), fatigue (85%), cough (78%), fever/chills (59%), and wheezing (52%). Reduced DLCO occurred in 54%. Only 9 of 27 patients had initially normal resting pulmonary function. HRCT findings included centrilobular nodules (81%), ground glass (58%), and air-trapping (50%). NTM were cultured from sputum or BAL in 17 (65%). Twelve cases were treated with antibiotics plus steroids, 13 with steroids alone, and 2 with exposure removal only. Significant improvement or disease resolution occurred in all. Air and water cultures of implicated hot tubs and pools in 11 patients showed a mean NTM water concentration of 115,585 cfu/ml (range: 32-600,000) and a mean air concentration of 3643 cfu/M³ (range: 15-9,424). **Conclusions:** Exposure to NTM aerosols from contaminated pools and spas may cause a granulomatous lung disease with features of HP. Early recognition and management leads to a favorable prognosis.

This Abstract is Funded by: National Jewish Medical and Research Center

Smad3 KO Mice Are Resistant to TGF- β 1 Mediated Fibrogenesis and Induce a Pro-Fibrotic Microenvironment

P. Bonniaud^{1,2}, M. Kolb¹, T. Galt¹, A.B. Roberts³, P.J. Margetts¹, J. G. ¹McMaster University, Hamilton, ON, Canada; ²CHU et Université de Bourgogne, Dijon, France; ³National Institutes of Health, Bethesda, MD.

TGF- β 1 is one of the key cytokines involved in the pathogenesis of pulmonary fibrosis. Smads are a family of signal transducer proteins with Smad3 mediating directly signaling from activated TGF- β 1 receptor type I. Smad3 deficiency attenuated bleomycin induced lung fibrosis in mice (Zhao et al). We assessed fibrosis development and fibrotic gene responses in smad3 null mice after direct transient TGF- β expression in lung.

Adenovirus encoding for active TGF- β 1 (AdTGF- β 1) was administered (intranasally) to smad3 KO or WT mice. Fibrosis extent was evaluated at day 28 (5 group). Total lung RNA from treated mice 4 days after vector instillation (4 to 5) was analysed by quantitative RT-PCR analysis for known TGF- β related gene expression.

At day 28 after AdTGF- β 1, lungs showed large amounts of fibrotic tissue, confirmed by histology with trichrome masson and picrosirius red staining in WT mice. Evidence of fibrosis was observed in KO mice. This difference was confirmed by hydroxyproline assay. By day 4 after AdTGF- β 1, WT mice showed an expected increase in matrix components (procollagen3a1, CTGF), antiproteases (TIMP-1) and α SMA mRNA expression. There was no difference between WT or KO mice before treatment and no significant increased expression of these genes in KO mice at day 4 after adenoviral exposure. These data were confirmed in primary fibroblast lines exposed to rTGF- β 1 (1ng/ml).

Conclusion: Blocking TGF- β 1 responses by targeting Smad3 inhibits the progression of the necessary microenvironment leading to fibrosis.

This Abstract is Funded by: CIHR Canada, Bourses Lavoisier, Ligue Belge Contre le Cancer

Complement Receptor 1 Gene Polymorphisms in Idiopathic Pulmonary Fibrosis

M. Luisetti¹, M. Zorzetto¹, I. Ferrarotti¹, R. Scabini¹, R. Trisolini², V. Poletti Patelli², M. Novo¹, L. Lazzari Agli², M. Cuccia⁴, M. Martinetti⁵, E. Pozzi¹. ¹Clinica Malattie Apparato Respiratorio, IRCCS Policlinico San Matteo, Università di Pavia, Pavia, Italy; ²Dipartimento di Malattie del Torace, Ospedale Maggiore, Bologna, Italy; ³U.O. Endoscopia Toracica, Ospedale G.B. Morgagni, Forlì, Italy; ⁴Dipartimento Genetica e Microbiologia, Università di Pavia, Pavia, Italy; ⁵Servizio di Immunologia e Trasfusione e Centro di Immunologia dei Trapianti, IRCCS Policlinico San Matteo, Pavia, Italy. Email: m.luisetti@smatteo.pv.it

Erythrocyte (E) complement receptor 1 (CR1) is a membrane protein mediating transport of immune complexes (ICs) to phagocytes. Three polymorphic sites of CR1 gene (His1208Arg, intron 27 HindIII RFLP, and Pro1827Arg) are related to surface density of CR1, in turn related to the rate of IC clearance. We previously demonstrated an association between sarcoidosis and CR1 genotypes coding reduced CR1/E ratio (Zorzetto et al AJRCMB 2002;27:17). Since Idiopathic Pulmonary Fibrosis (IPF) shares with sarcoidosis the hypothesis of putative triggering etiologic factor(s), we hypothesized that a late clearance of ICs might be involved in pathogenesis of IPF too. To this aim we analyzed the 3 CR1 polymorphisms by RFLP and direct sequencing in a group of 73 patients affected by IPF, as well as in sex-, age-, and ethnicity-matched controls. We first had evidence that the intron HindIII RFLP is a T-to-C substitution nt 520 (GeneBank accession number AY 1585). The 3 polymorphisms were in strong linkage disequilibrium. The GG genotype for Pro1827Arg (C5507G) polymorphism, related to an E surface low density of CR1 molecules, was significantly associated with IPF in comparison to controls ($X^2 = 8.74$, OR = 6.86, 95% CI 2.00 - 14.93). These findings are consistent with a novel, possibly susceptibility gene factor for IPF. Moreover, it opens to intriguing speculations about susceptibility factor shared by two interstitial lung disease, sarcoidosis and IPF.


This Abstract is Funded by: IRCCS Policlinico San Matteo

Augmented Pulmonary IL-4 and IL-13 Receptor Subunit Expression in Idiopathic Interstitial Pneumonia

C. Jakubzick¹, S.L. Kunkel¹, F.J. Martinez¹, K.R. Flaherty¹, R.K. Purii², G.B. Toews¹, T. Colby³, W.D. Travis⁴, J.P. Lynch III⁵, C.M. Hogaboam¹. ¹University of Michigan Medical School, Ann Arbor, MI; ²Laboratory of Molecular Tumor Biology, FDA, Bethesda, MD; ³Mayo Clinic, Scottsdale, AZ; ⁴Armed Forces Institute of Pathology, Washington, DC.

Some idiopathic interstitial pneumonias (IIP) are characterized by fibro-proliferative. Since efficacious treatments are limited, research has been directed towards understanding the cytokine networks associated with IIPs. In the present study, we hypothesized that severe IIP is dominated by interleukin-4 (IL-4) and IL-13 due to the abnormal expression of their corresponding receptor subunits. [figure 1] Molecular, protein, and biochemical analysis of surgical lung biopsies (SLB) from patients suspected of having IIP ($n=45$) demonstrated that IL-4 and IL-13 were present in higher levels in biopsies from patients with histologically confirmed usual interstitial pneumonia (UIP; $n=18$) and non-specific interstitial pneumonia-fibrotic form (NSIP-fibrotic; $n=7$) compared with patients with lesser aggressive forms of IIP ($n=8$) and non-IIP ($n=12$) controls. Immunohistochemical analysis revealed that fibroblastic foci in UIP and NSIP-fibrotic patients strongly stained for the presence of the IL-4 receptor alpha (IL-4R α) and IL-13R α 2. Thus, this study demonstrates that some histologic subtypes of IIP are associated with increased pulmonary expression of receptor subunits responsive to IL-4 and IL-13. These findings may be of particular importance in describing the pathogenesis of IIPs and, more importantly, may provide important novel therapeutic targets.

This Abstract is Funded by: NIH P50HL56402-04





AMERICAN JOURNAL OF

Respiratory and Critical Care Medicine

Volume 167 • Number 7 • April 2003

Abstracts

2003
INTERNATIONAL
CONFERENCE

May 16–21, SEATTLE, WASHINGTON
AMERICAN THORACIC SOCIETY

This is a supplement of the American Journal of Respiratory and Critical Care Medicine

AN OFFICIAL JOURNAL OF THE AMERICAN THORACIC SOCIETY